1. Home
  2. GYRE

as of 11-20-2026 10:49am EST

$4.33
$0.18
-3.99%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Founded: 2002 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 625.6M IPO Year: 2004
Target Price: $18.67 AVG Volume (30 days): 210.5K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: annual
EPS: -0.29 EPS Growth: -60.00
52 Week Low/High: $3.97 - $9.14 Next Earning Date: 11-05-2026
Revenue: $275,000 Revenue Growth: -92.42%
Revenue Growth (this year): -6.08% Revenue Growth (next year): 27.49%
P/E Ratio: -15.55 Index:
Free Cash Flow: -180000.0 FCF Growth: N/A

AI-Powered GYRE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

hold
Model Precision: 43.75%
43.75%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 5, 2026 · 100% conf.

AI Prediction BUY

1D

+4.15%

$4.62

Act: +17.71%

5D

+8.01%

$4.80

20D

+5.21%

$4.67

Price: $4.44 Prob +5D: 100% AUC: 1.000
0001193125-26-449985

EX-99.1

2 gyre-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04)

Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed

SAN DIEGO, November 5, 2026 -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), a U.S. biopharmaceutical company with research operations and commercial business in China to advance global development of protein degrader therapeutics, today announced financial results for the third quarter ended September 30, 2026, and provided a business update.

Dr. Ying Luo, President and Chief Executive Officer of Gyre Therapeutics, commented, “I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027. Together, these programs are expected to drive our next phase of growth and demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China.”

Third Quarter Business Highlights and Upcoming Milestones

Pipeline Development Updates

F351 (hydronidone)

In May 2026, Gyre announced that the Center for Drug Evaluation (CDE) of the NMPA accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis. The acceptance came after Gyre submitted the NDA through its majority-owned subsidiary Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals) following the priority review status for F351 granted by the NMPA in March 2026. During the third quarter, Gyre Pharmaceuticals completed an on-site inspection conducted by the NMPA of its manufacturing plants and clinical centers. Gyre believes a decision from the NMPA could occur by the end of 2026 or in the first quarter of 2027.

1

CG001419 for cancer pain and solid tumors

Following the successful completion of a Phase 1 study in Australia of 78 healthy volunteers in December 2025, Gyre is now planning a Phase 2 study to further evaluate CG001419 in cancer-induced bone pain (CIBP) and other metastatic cancer pain syndromes in China to initiate in the first half of 2027.

CG001419 continues to separately be evaluated in a Phase 1 trial in China for the treatment of solid tumors.

CG009301 for AML

CG009301 is a GSPT1 degrader for acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow. This candidate continues to be studied in a Phase 1 dose-escalation trial being conducted in China in patients with high-risk hematologic malignancies. We anticipate Phase 1 dose-escalation data to be available in the second half of 2027.

Dual-degrader programs (next-generation targeted protein degraders)

Gyre expects to submit Investigational New Drug (IND) applications and initiate Phase 1 clinical trials, upon regulatory approval of IND applications, in the United States and/or China around mid-2027 for CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications, and CG620953, a TYK2-JAK1 dual degrader for autoimmune diseases.

DACs, next-generation ADCs

Additional developments from our in-house R&D efforts include discovery/preclinical stage degrader antibody conjugate (DAC) candidates for solid tumors and hematological malignancies, which are considered the next generation of antibody drug conjugates (ADCs). These DACs consist of distinct protein degraders paired with tumor-specific antibodies. We continue to make progress as we screen to identify leads and look to provide more details on our first IND-ready DAC candidate(s) in 2027.

Pirfenidone for Pneumoconiosis

A Phase 3 trial of pirfenidone for the treatment of pneumoconiosis in China completed enrollment in 2025. A total of 272 patients were enrolled evaluating the efficacy and safety of 52 weeks of pirfenidone capsule treatment in patients with pneumoconiosis versus placebo. The potential for additional patient enrollment is currently being evaluated to replace patients that have dropped out of the study.

2

Pirfenidone for Radiation-Induced Lung Injury (RILI)

In April 2026, Gyre Pharmaceuticals initiated its adaptive Phase 2/3 clinical trial in oncology-related pulmonary complications, with the first patient enrolled. The trial is evaluating pirfenidone for RILI, including cases complicated by immune-related pneumonitis, at leading oncology centers.

Commercial Products:

ETUARYTM (pirfenidone for IPF), Etorel™ and Contiva™

ETUARY (pirfenidone), the Company's primary product appro

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 7, 2026 · 97% conf.

AI Prediction SELL

1D

-7.48%

$6.07

Act: -2.13%

5D

-12.01%

$5.77

20D

-23.44%

$5.02

Price: $6.56 Prob +5D: 1% AUC: 1.000
0001193125-26-339223

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1786365079.ca12303b

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q2

Q2 2026 Earnings

8-K/A SELL

Jul 15, 2026 · 97% conf.

AI Prediction SELL

1D

-7.48%

$6.07

Act: -2.13%

5D

-12.01%

$5.77

20D

-23.44%

$5.02

Price: $6.56 Prob +5D: 1% AUC: 1.000
0001140361-26-028564

EX-99.1

3 ef20077460_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and the Board of Directors of Cullgen Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Cullgen Inc. (the Company) as of December 31, 2025, the related consolidated statements of comprehensive loss, redeemable convertible preferred stock and stockholders’ deficit and cash flows for the year then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025, and the results of its operations and its cash flows for the year then ended, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young Hua Ming LLP

We have served as the Company’s auditor since 2025.

Shanghai, the People’s Republic of China

July 15, 2026

1

INDEX TO CULLGEN’S CONSOLIDATED FINANCIAL STATEMENTS

Page

Consolidated Balance Sheet as of December 31, 2025

3

Consolidated Statement of Comprehensive Loss for the Year Ended December 31, 2025

4

Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Deficit for the Year Ended December 31, 2025

5

Consolidated Statement of Cash Flows for the Year Ended December 31, 2025

6

Notes to audited Consolidated Financial Statement for the Year Ended December 31, 2025

7

2

Index

Cullgen Inc.

Consolidated Balance Sheet

(in thousands, except share and per share data)

December 31,

2025

Assets

Current assets:

Cash and cash equivalents

$

12,122

Short-term investments

28,085

Prepaid expenses and other current assets

6,786

Amounts due from related parties

-

Total current assets

46,993

Non-current assets:

Property and equipment, net

3,951

Operating lease right-of-use assets

2,478

Other non-current assets

209

Total non-current assets

6,638

Total assets

$

53,631

Liabilities, redeemable convertible preferred stock, and stockholders’ deficit

Current liabilities:

Accounts payable

$

1,211

Accrued expenses and other current liabilities

2,633

Operating lease liabilities, current

483

Deferred revenue, current

1,170

Total current liabilities

5,497

Non-current liabilities:

Operating lease liabilities, non-current

2,001

Deferred revenue, non-current

57

Total non-current liabilities

2,058

Total liabilities

7,555

Commitments and contingencies (Note 15)

Redeemable convertible preferred stock, $0.0001 par value per share, 57,821,355 shares authorized, 57,821,355 shares issued and outstanding as of December 31, 2025; aggregate liquidation preference of $116,000 as of December 31, 2025.

173,467

Stockholders’ deficit:

Common stock, $0.0001 par value per share, 143,329,269 shares authorized, 10,023,615 shares issued and outstanding as of December 31, 2025

1

Additional paid-in capital

5,127

Accumulated deficit

(132,179

)

Accumulated other comprehensive loss

(340

)

Total stockholders’ deficit

(127,391

)

Total liabilities, redeemable convertible pref

Share on Social Networks: